Article info
Research ethics
Patients' perceptions of information provided in clinical trials
- Correspondence to: Professor P R Ferguson, Department of Law, University of Dundee, Park Place, Dundee, DD1 4HN, UK; p.r.ferguson{at}dundee.ac.uk
Citation
Patients' perceptions of information provided in clinical trials
Publication history
- Accepted July 9, 2001
- Revised July 8, 2001
- First published February 1, 2002.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2002 by the Journals of Medical Ethics
Other content recommended for you
- Quantitative aspects of informed consent: considering the dose response curve when estimating quantity of information
- Decision aids for randomised controlled trials: a qualitative exploration of stakeholders’ views
- An empirical study on the preferred size of the participant information sheet in research
- Parental understanding of our communication of morbidity associated with paediatric cardiac surgery: a qualitative study
- How do patients feel about taking part in clinical trials in emergency care?
- Patients’ values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: a protocol for a multinational structured interview-based study combined with a randomised survey on the optimal amount of information to elicit preferences
- Informed consent in medical research: Journals should not publish research to which patients have not given fully informed consent–with three exceptions
- Group interventions for amyotrophic lateral sclerosis caregivers in Ireland: a randomised controlled trial protocol
- Development of patient decision support tools for motor neuron disease using stakeholder consultation: a study protocol
- Equipoise, standard of care and consent: responding to the authorisation of new COVID-19 treatments in randomised controlled trials